These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34898559)

  • 1. The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma.
    Banerji S; Meyers DE; Harlos C; Dawe DE
    Curr Oncol; 2021 Nov; 28(6):4542-4551. PubMed ID: 34898559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
    Laune Q; Brosseau S
    Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
    Cui W; Popat S
    Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab plus ipilimumab in malignant pleural mesothelioma.
    Travert C; Tomasini P; Greillier L
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
    Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Advanced Pleural Mesothelioma-At the Crossroads.
    Nowak AK; Jackson A; Sidhu C
    JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
    McNamee N; Harvey C; Gray L; Khoo T; Lingam L; Zhang B; Nindra U; Yip PY; Pal A; Clay T; Arulananda S; Itchins M; Pavlakis N; Kao S; Bowyer S; Chin V; Warburton L; Pires da Silva I; John T; Solomon B; Alexander M; Nagrial A
    J Thorac Oncol; 2024 Apr; 19(4):636-642. PubMed ID: 38036250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
    Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
    EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
    Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
    Hu ZI; Ghafoor A; Sengupta M; Hassan R
    Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Uprety D
    Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Kim RY; Li Y; Marmarelis ME; Vachani A
    Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
    Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
    Adler AI; Slayen S; Stegenga H; Guo Y; Diaz R; Welton NJ; Westwood N; Doull I; Crawley C
    Lancet Respir Med; 2022 Oct; 10(10):e92-e93. PubMed ID: 35988573
    [No Abstract]   [Full Text] [Related]  

  • 20. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
    Desai AP; Kosari F; Disselhorst M; Yin J; Agahi A; Peikert T; Udell J; Johnson SH; Smadbeck J; Murphy S; Karagouga G; McCune A; Schaefer-Klein J; Borad MJ; Cheville J; Vasmatzis G; Baas P; Mansfield A
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37279993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.